REDF

Redx Pharma is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics for the treatment of fibrotic diseases and cancer. The company leverages its deep expertise in medicinal chemistry to target complex biological pathways, such as the Wnt and ROCK pathways, which are central to disease progression in high-need areas. Its lead programs include zelasudil (RXC007), a selective ROCK2 inhibitor for idiopathic pulmonary fibrosis, and RXC004, a Porcupine inhibitor being evaluated for various solid tumors. Redx has a proven track record of early-stage discovery, having successfully partnered programs with major pharmaceutical companies like AstraZeneca and Jazz Pharmaceuticals.